Objective: To analyze the effect of 'double C' therapy combined with glibenclamide in the treatment of GDM and its influence on serum omentin-1 and VF levels. Methods: 100 patients with GDM admitted to our hos...Objective: To analyze the effect of 'double C' therapy combined with glibenclamide in the treatment of GDM and its influence on serum omentin-1 and VF levels. Methods: 100 patients with GDM admitted to our hospital from January 2016 to May 2018 were randomly divided into observation group and control group. The control group was treated with routine treatment, while the observation group was treated with 'double C' therapy combined with glibenclamide. Blood sugar level, cesarean section rate, premature delivery rate, pregnancy-induced hypertension rate, fetal distress and incidence of macrosomia were investigated. The levels of omentin-1 and VF in serum were measured. Results: The levels of HbA1c, FPG, 1 h PBG and 2 h PBG in blood of the two groups before delivery were significantly lower than those of the control group (P<0.05), and the levels of HbA1c, FPG, 1 h PBG and 2 h PBG in the observation group were significantly lower than those in the control group (P<0.05);the levels of omentin-1 and VF in the two groups before delivery were significantly higher (P<0.05), and the levels of omentin-1 in the observation group were significantly higher than those in the control group (P<0.05). After treatment, the rate of cesarean section, premature delivery, pregnancy-induced hypertension, fetal distress and macrosomia in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusions: The combination of double C therapy and glibenclamide can improve the curative effect of GDM and the levels of omentin-1 and VF in blood.展开更多
BACKGROUND Necrotising enterocolitis(NEC)is a critical gastrointestinal emergency affecting premature and low-birth-weight neonates.Serum amyloid A(SAA),procalcitonin(PCT),and high-mobility group box 1(HMGB1)have emer...BACKGROUND Necrotising enterocolitis(NEC)is a critical gastrointestinal emergency affecting premature and low-birth-weight neonates.Serum amyloid A(SAA),procalcitonin(PCT),and high-mobility group box 1(HMGB1)have emerged as potential biomarkers for NEC due to their roles in inflammatory response,tissue damage,and immune regulation.AIM To evaluate the diagnostic value of SAA,PCT,and HMGB1 in the context of NEC in newborns.METHODS The study retrospectively analysed the clinical data of 48 newborns diagnosed with NEC and 50 healthy newborns admitted to the hospital.Clinical,radiological,and laboratory findings,including serum SAA,PCT,and HMGB1 Levels,were collected,and specific detection methods were used.The diagnostic value of the biomarkers was evaluated through statistical analysis,which was performed using chi-square test,t-test,correlation analysis,and receiver operating characteristic(ROC)analysis.RESULTS The study demonstrated significantly elevated levels of serum SAA,PCT,and HMGB1 Levels in newborns diagnosed with NEC compared with healthy controls.The correlation analysis indicated strong positive correlations among serum SAA,PCT,and HMGB1 Levels and the presence of NEC.ROC analysis revealed promising sensitivity and specificity for serum SAA,PCT,and HMGB1 Levels as potential diagnostic markers.The combined model of the three biomarkers demonstrating an extremely high area under the curve(0.908).CONCLUSION The diagnostic value of serum SAA,PCT,and HMGB1 Levels in NEC was highlighted.These biomarkers potentially improve the early detection,risk stratification,and clinical management of critical conditions.The findings suggest that these biomarkers may aid in timely intervention and the enhancement of outcomes for neonates affected by NEC.展开更多
基金National Natural Science Foundation of China.Project No:81402147.
文摘Objective: To analyze the effect of 'double C' therapy combined with glibenclamide in the treatment of GDM and its influence on serum omentin-1 and VF levels. Methods: 100 patients with GDM admitted to our hospital from January 2016 to May 2018 were randomly divided into observation group and control group. The control group was treated with routine treatment, while the observation group was treated with 'double C' therapy combined with glibenclamide. Blood sugar level, cesarean section rate, premature delivery rate, pregnancy-induced hypertension rate, fetal distress and incidence of macrosomia were investigated. The levels of omentin-1 and VF in serum were measured. Results: The levels of HbA1c, FPG, 1 h PBG and 2 h PBG in blood of the two groups before delivery were significantly lower than those of the control group (P<0.05), and the levels of HbA1c, FPG, 1 h PBG and 2 h PBG in the observation group were significantly lower than those in the control group (P<0.05);the levels of omentin-1 and VF in the two groups before delivery were significantly higher (P<0.05), and the levels of omentin-1 in the observation group were significantly higher than those in the control group (P<0.05). After treatment, the rate of cesarean section, premature delivery, pregnancy-induced hypertension, fetal distress and macrosomia in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusions: The combination of double C therapy and glibenclamide can improve the curative effect of GDM and the levels of omentin-1 and VF in blood.
文摘BACKGROUND Necrotising enterocolitis(NEC)is a critical gastrointestinal emergency affecting premature and low-birth-weight neonates.Serum amyloid A(SAA),procalcitonin(PCT),and high-mobility group box 1(HMGB1)have emerged as potential biomarkers for NEC due to their roles in inflammatory response,tissue damage,and immune regulation.AIM To evaluate the diagnostic value of SAA,PCT,and HMGB1 in the context of NEC in newborns.METHODS The study retrospectively analysed the clinical data of 48 newborns diagnosed with NEC and 50 healthy newborns admitted to the hospital.Clinical,radiological,and laboratory findings,including serum SAA,PCT,and HMGB1 Levels,were collected,and specific detection methods were used.The diagnostic value of the biomarkers was evaluated through statistical analysis,which was performed using chi-square test,t-test,correlation analysis,and receiver operating characteristic(ROC)analysis.RESULTS The study demonstrated significantly elevated levels of serum SAA,PCT,and HMGB1 Levels in newborns diagnosed with NEC compared with healthy controls.The correlation analysis indicated strong positive correlations among serum SAA,PCT,and HMGB1 Levels and the presence of NEC.ROC analysis revealed promising sensitivity and specificity for serum SAA,PCT,and HMGB1 Levels as potential diagnostic markers.The combined model of the three biomarkers demonstrating an extremely high area under the curve(0.908).CONCLUSION The diagnostic value of serum SAA,PCT,and HMGB1 Levels in NEC was highlighted.These biomarkers potentially improve the early detection,risk stratification,and clinical management of critical conditions.The findings suggest that these biomarkers may aid in timely intervention and the enhancement of outcomes for neonates affected by NEC.
